Table 3.
Ongoing clinical studies evaluating the prophylactic role of CQ and HCQ against COVID‐19 (search conducted on clinicaltrials.gov on 30 March 2020)
| Study registration no. (country) | Recruitment status | No. of Centers and study design | Population (volunteers) | Interventional group(s) | Comparison Group(s) | Primary Outcomes |
|---|---|---|---|---|---|---|
| NCT04308668 (USA) | Recruiting | Multi‐center randomized parallel group trial | 1500 participants (contact or healthcare worker exposed to a patient with COVID‐19) | HCQ | Placebo | Incidence and severity of COVID‐19 |
| NCT04304053 (Spain) | Recruiting | Multi‐center cluster randomized trial | 3040 participants (Contacts of patients with COVID‐19) | Antiviral treatment and prophylaxis with HCQ | Standard public health measures | Incidence of secondary COVID‐19 cases |
| NCT04303507 (Europe & Asia) | Not yet recruiting | Multi‐center randomized parallel group trial | 40000 participants (contact or healthcare worker exposed to a patient with COVID‐19) | CQ or HCQ | Placebo | Number of symptomatic COVID‐19 infections |
| NCT04318444 (USA) | Not yet recruiting | Community‐Based Randomized Clinical Trial | 1600 participants (adult household contacts of COVID‐19 patients | HCQ | Placebo | Number of participants with symptomatic, lab‐confirmed COVID‐19 |
| NCT04318015 (Mexico) | Not yet recruiting | Parallel group RCT | 400 participants (healthcare workers attending to COVID‐19 patients) | HCQ | Placebo | Symptomatic COVID‐19 |
Abbreviations: CQ, chloroquine; HCQ, hydroxychloroquine.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.